No Data
No Data
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading
Bicycle Therapeutics Says Eric Westin Promoted to Chief Medical Officer >BCYC
Bicycle Therapeutics Announces Felix Baker to Become Chairman of Board of Directors >BCYC
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $30
Promising Upside for Bicycle Therapeutics: Buy Rating Backed by Positive Clinical Data and Market Potential for ZP Treatment